Same molecule, different label, ten times the price

The pairs

Four of the biggest brand names in this market are two molecules. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Tirzepatide is sold as Mounjaro for diabetes and as Zepbound for weight. Liraglutide is Victoza and Saxenda. Oral semaglutide is Rybelsus for diabetes and the Wegovy pill for weight.

What the manufacturers actually say

• ◆Ozempic is indicated “along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes,” plus cardiovascular and kidney risk reduction in specific diabetic populations.
• ◆Mounjaro is indicated “along with diet and exercise to improve blood sugar (glucose) in adults and children 10 years of age and older with type 2 diabetes mellitus.”
• ◆Rybelsus is indicated for blood sugar in type 2 diabetes and cardiovascular risk reduction in high-risk diabetic patients. Weight loss is not a stated indication.
• ◆Trulicity is indicated for blood sugar in adults and children 10 and over with type 2 diabetes, plus cardiovascular risk reduction. It has no weight-management sibling at all.
• ◆Victoza is indicated for blood sugar in adults and children 10 and over with type 2 diabetes, plus cardiovascular risk reduction in adults with known heart disease.
• ◆Wegovy, Zepbound and Foundayo carry the chronic weight-management indications. Saxenda does too — including for children aged 12–17 above 132 lbs — but is being discontinued.

And now the prices

The pattern is consistent: the weight-management brands have aggressive manufacturer self-pay programmes and the diabetes brands do not. That inverts the intuition that a diabetes drug should be the cheaper one, and it is the single most useful thing to understand before comparing quotes.

What this means in practice

• ◆If you are being treated for weight, the weight-management brand is both the correct label and — right now — the cheaper one. Ask specifically about Wegovy and Zepbound rather than Ozempic and Mounjaro.
• ◆If you have type 2 diabetes, the diabetes brand is the one your insurer is far more likely to cover, and the savings programmes still apply: Lilly offers “as little as $25 for up to a 3-month prescription” on Mounjaro with commercial coverage.
• ◆A quote of $1,000–$1,900 a month for tirzepatide or semaglutide means no manufacturer programme is being applied. That is worth challenging before accepting.
• ◆Rybelsus has an administration requirement the others do not: take it “on an empty stomach in the morning with water (no more than 4 ounces),” then wait 30 minutes before eating, drinking or taking other oral medicines.